EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with STEMI Study Design Multicenter, multinational, prospective, randomized, two-arm, single-blind, controlled 1504 patients (all comers) who presented with STEMI within 48 hours of symptom onset, required emergent PCI, and had a target vessel diameter sufficient to accommodate currently available stents, randomized to receive an everolimus-eluting stent or a cobalt-chromium stent Primary Endpoint Composite endpoint of all-cause death, any MI, any revascularization

EXAMINATION Secondary Endpoints (at 1 year and yearly up to 5 years) All-cause and cardiac mortality Recurrent MI TLR and TVR Clinical device and procedure success Major and minor bleeding 1-Year Results A similar proportion of patients in the DES and BMS groups remained free from the primary endpoint Several individual endpoints were also similar, including freedom from cardiac death, recurrent MI, and repeat revascularization

EXAMINATION Primary Endpoint Composite endpoint of all-cause death, any MI, any revascularization

EXAMINATION Conclusions These results support the 2010 ESC guideline preference for DES over BMS in patients who have no contraindications to prolonged dual antiplatelet therapy The observation of a reduction in definite and definite/probable stent thrombosis in this modestly powered single-blind (subject) trial requires validation In applying results to clinical practice, it should be noted that there was high utilization (90%) of dual antiplatelet therapy through 1 year